SIRT1 Overexpression

CI-VAR-00003145Explore in graph →CIViC 529

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Pancreatic Neoplasm1
SIRT1 Overexpression	Niacinamide	Predictive	D	Supports Resistance	1	accepted	EID1294 In-vitro study with MiaPaCa-2 and PANC-1 pancreatic cancer cell lines. Inhibition of Sirt1 by increasing concentrations of nicotinamide led to a decrease in viability. Gefitinib treatment with concent… (full text at CIViC) PMID 24088390 · Stenzinger et al., 2013 · Open in CIViC	civic
Pancreatic Ductal Carcinoma1unmapped disease
SIRT1 Overexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID1293 Nuclear Sirt1 expression was identified by IHC in 36 (27.9%) of 129 pancreatic ductal adenocarcinoma cases. SIRT1 expression was associated with poor survival in univariate (p = 0.002) and multivariat… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.